Company Profile
ThermoGenesis Stock Price, News & Catalysts
- Ticker:
- THMO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (-99.00%)
Close
Last updated: August 4, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for THMO.
Company overview
Business overview
ThermoGenesis was a biotechnology company focused on cell processing, cell banking, and manufacturing systems for regenerative medicine. Its business sat at the intersection of tools, services, and cell-therapy enablement.
Geographic Base and Sector Classification
ThermoGenesis was headquartered in the United States and listed on NASDAQ. It sat in biotechnology tools and cell-processing infrastructure.
Business Model Characteristics
The company depended on platform adoption, manufacturing workflow demand, and the ability to monetize cell-processing technology. Investors historically watched commercial traction and strategic changes.
Position Within the Biotechnology Landscape
ThermoGenesis belongs in the cell-processing infrastructure layer of biotech. It is not a classic drug stock, but it supported the manufacturing ecosystem around regenerative medicine.
Future catalysts
- ThermoGenesis is largely a legacy and closeout story now, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it like a fresh growth name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ThermoGenesis (THMO)?
ThermoGenesis (THMO) most recently closed at 0.00 USD, a -99.00% move versus the previous session.
What does ThermoGenesis do?
ThermoGenesis was a biotechnology company focused on cell processing, cell banking, and manufacturing systems for regenerative medicine. Its business sat at the intersection of tools, services, and cell-therapy enablement.
On which exchange is THMO stock listed?
ThermoGenesis (THMO) is associated with NASDAQ, United States, Biopharma.
What is ThermoGenesis?
ThermoGenesis is largely a legacy and closeout story now, with catalysts limited to any strategic or asset-resolution update.
Which conditions is ThermoGenesis targeting with ThermoGenesis?
ThermoGenesis is largely a legacy and closeout story now, with catalysts limited to any strategic or asset-resolution update.
How does ThermoGenesis describe recent progress with ThermoGenesis?
ThermoGenesis is largely a legacy and closeout story now, with catalysts limited to any strategic or asset-resolution update.
What future catalysts are investors watching for ThermoGenesis?
ThermoGenesis is largely a legacy and closeout story now, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it like a fresh growth name.